Cardlytics Net Worth
Cardlytics Net Worth Breakdown | CDLX |
Cardlytics Net Worth Analysis
Cardlytics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cardlytics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cardlytics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cardlytics' net worth analysis. One common approach is to calculate Cardlytics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cardlytics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cardlytics' net worth. This approach calculates the present value of Cardlytics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cardlytics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cardlytics' net worth. This involves comparing Cardlytics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cardlytics' net worth relative to its peers.
To determine if Cardlytics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cardlytics' net worth research are outlined below:
Cardlytics generated a negative expected return over the last 90 days | |
Cardlytics has high historical volatility and very poor performance | |
Cardlytics has high likelihood to experience some financial distress in the next 2 years | |
Cardlytics currently holds 221.65 M in liabilities with Debt to Equity (D/E) ratio of 0.42, which is about average as compared to similar companies. Cardlytics has a current ratio of 0.88, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Cardlytics' use of debt, we should always consider it together with its cash and equity. | |
The entity reported the previous year's revenue of 278.3 M. Net Loss for the year was (189.3 M) with profit before overhead, payroll, taxes, and interest of 120.89 M. | |
Cardlytics currently holds about 157.04 M in cash with (8.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Cardlytics has a poor financial position based on the latest SEC disclosures | |
Roughly 58.0% of Cardlytics shares are held by institutions such as insurance companies |
Cardlytics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cardlytics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cardlytics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View |
Follow Cardlytics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 128.65 M.Project Cardlytics' profitablity
The company has Profit Margin (PM) of (0.68) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11.When accessing Cardlytics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cardlytics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cardlytics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cardlytics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cardlytics. Check Cardlytics' Beneish M Score to see the likelihood of Cardlytics' management manipulating its earnings.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cardlytics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cardlytics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cardlytics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cardlytics time-series forecasting models is one of many Cardlytics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cardlytics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Cardlytics Earnings per Share Projection vs Actual
Cardlytics Corporate Management
Evelyne Forester | Chief Officer | Profile | |
Carson Napps | Chief Officer | Profile | |
Jose Singer | Chief Officer | Profile | |
Alexis DeSieno | Chief Officer | Profile | |
Karim Temsamani | CEO Director | Profile | |
James Hart | VP People | Profile |
Additional Tools for Cardlytics Stock Analysis
When running Cardlytics' price analysis, check to measure Cardlytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardlytics is operating at the current time. Most of Cardlytics' value examination focuses on studying past and present price action to predict the probability of Cardlytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardlytics' price. Additionally, you may evaluate how the addition of Cardlytics to your portfolios can decrease your overall portfolio volatility.